The global human coagulation factor market was estimated at USD 9,875.4 million in 2021 and is projected to reach USD 15,930.3 million by 2028, showing a CAGR of 6.0% during the forecast period 2022-2028. The major elements driving the market growth include the growing patient population base, R&D movements, and increasing emphasis on recombinant products by pharmaceutical companies. Arising markets offer considerable growth opportunities for the global coagulation factor market.
Human Coagulation factors are proteins in the blood that aid control bleeding. You have several various coagulation factors in your blood. When you have an injured or another cut that causes bleeding, your coagulation factors work jointly to form a blood clot. The clot controls you from losing too much blood. This procedure is called the coagulation cascade. Blood coagulation is a complicated, multi-step procedure that needs many other various coagulation factors. These factors must work jointly in a coordinated series to produce a blood clot when there is harm to the blood vessels. The clotting procedure can be fast and efficient.
The increasing number of growing patients with bleeding disorders is a significant driver of the coagulation factor market. More than 1,125,000 men globally suffer from genetic coagulation disorder, with 418,000 suffering from a mild form of the often-undiagnosed disease. Haemophilia is the most general condition, impacting over 195 thousand patients in 2019, and 80 thousand people were living with von Willebrand disorder, statistic states. Around 18,000 patients with hemophilia and over 12 thousand with von Willebrand disorder in the United States alone. By the CDC, Von Willebrand’s disease impacts about 1% of the population. On the other hand, women are especially targeted by Von Willebrand infection due to their menstrual cycle. This extensive pool of patients is being treated with some treatment method; thus, the market for coagulation factor treatment has been growing.
Many industries and scientific institutions have endeavored to find new medicines and strengthen existing medications that make multiple patients aware of treatment and expand the adoption rate. St. Jude’s physicians and specialists have been developing and enhancing therapies for children with bleeding disorders for over 50 years. They work with a federally established Hemophilia Rehab Center and children’s treatment services around the country. Researchers at Children’s Hospital of Philadelphia have designed a theoretically safer and more efficient gene therapy vector for coagulation factors, focusing on sickle cell disease and beta-thalassemia. Many replacement drugs have been developed with simpler administration methods, lower immunogenicity, greater potency, and longer half-lives. Bioengineering advances have been helping in treating coagulation disorders for the past five years. These advancements increase the coagulation factor treatment market growth.
The high expense of treatment is a significant barrier to the market. Daily outpatient appointments, hospitalization, and lab studies entail high costs unaffordable for middle-income nations such as Asia and Africa; thus, the consequence of coagulation factors treatments in those regions is stagnant. Furthermore, a shortage of clinicians in emerging and underdeveloped nations and an unfavorable reimbursement situation impede the human coagulation factor treatment market.
Before the covid-19, Hemophilia is a hereditary genetic disorder that impairs the body’s capability to control coagulation or blood clotting. In this disease, clotting factors regulating bleeding from a damaged vessel are deficient; therefore, coagulation does not occur. Of the two types of hemophilia, hemophilia A has a higher prevalence than the other variant hemophilia B. . Obtained hemophilia is a rare non-genetic form of hemophilia in which autoantibodies create against the plasma coagulation factor. The development of novel coagulating factors and technological advancements are driving the growth of this market.
During the covid-19 outbreak, the pandemic has affected the many clinical trials conducted to treat coagulation disorders. Since both hospitals are concentrated on coronavirus cases, patients with coagulation disorders often terminate their hospital appointments. In addition, hospitals canceled or delayed replacement treatments of hemophilia. Besides that, the supply chain of coagulation disorder medications or products has been disrupted because of the travel ban and lockdown imposed by the pandemic. As a result, coagulation disorder treatment is experiencing poor demand expansion in this pandemic situation.
After the covid-19 outbreak, increasing governmental schemes and aggressive campaigning have helped the growth of the human coagulation factor Treatment market in recent years. Especially the medical guidelines according to the COVID vaccination has enhanced the treatment and facilities related to Hemophilia Treatment in recent years. In recent years, the injectable administration showcases a growth rate of over 5%, owing to the increased life quality and improved overall treatment witnessed in coagulation patients.
Based on Type, the global human coagulation factor market is segmented into Injection and Freeze-dried Injection. Freeze-dried injection dominates the global human coagulation market, and dried human plasma consists of approximately 55 % of blood. It is a yellow color fluid. It is used for plasma transfusion where medically required. It was first generated in the British 1930. Collection Take blood from blood donors who want blood donations and are eligible for donating blood. The solution is to have a readily available product, easy to store, transport, and administer quickly and safely. Dried plasma provides all these advantages. It can be preserved for up to 2 years at room temperature and reconstituted within minutes.
The global human coagulation factor market is segmented into Hemophilia A and Relevant Bleeding Diseases based on application. The Hemophilia A type has share highest share in the global human coagulation factor market. The availability of therapies and medications has increased the demand for the Hemophilia Treatment market. Therapy of inhibitors, home treatment, free factor replacement, Ant fibrinolytic medications, gene therapy, and physical therapy are typically utilized therapies and medications used in Hemophilia treatment. These elements have constructed a huge positive impact on the Hemophilia Treatment market growth.
Based on region, the global human coagulation factor market is segmented into North America, Europe, Asia-Pacific, South America and The Middle East & Africa. North America is anticipated to maintain a major market share in the human coagulation factor market therapeutics market due to the increasing prevalence of different blood disorders and increasing awareness among the patient population in this region. Furthermore, expanding investments in research and development to develop treatment options for coagulation disorders and well-established healthcare infrastructure are also fueling the development of the overall regional market to a large scope.
The companies include CSL Behring, Baxter, Grifols, Octapharma, Zhongsheng Group, Taibang Bio, Shanghai Laishi, Hualan Bio, Hoffmann-La-Roche Ltd. and other prominent players in the global human coagulation factor market.
Key Stakeholders
| Report Attribute | Details |
|---|---|
| Revenue in 2021 | USD 9,875.4 million |
| The revenue forecast in 2028 | USD 15,930.3 million |
| Growth Rate | CAGR of 6.0% from 2022 to 2028. |
| Historical data | 2017 – 2020 |
| Forecast period | 2022 – 2028 |
| Region covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Key companies Profiled | The companies include CSL Behring, Baxter, Grifols, Octapharma, Zhongsheng Group, Taibang Bio, Shanghai Laishi, Hualan Bio, and Hoffmann-La-Roche Ltd players. |
By Type
By Application
By Region
Global Internet of Things (IoT) Market
Global Plant-Based Meat Market
Explosion-Proof Equipment Market
Autoclaved Aerated Concrete Market
Human Coagulation factors are proteins in the blood that aid control bleeding. You have several various coagulation factors in your blood. When you have an injured or another cut that causes bleeding, your coagulation factors work jointly to form a blood clot. The clot controls you from losing too much blood. This procedure is called the coagulation cascade.
The increasing number of growing patients with bleeding disorders is a significant driver of the coagulation factor market. More than 1,125,000 men globally suffer from genetic coagulation disorder, with 418,000 suffering from a mild form of the often-undiagnosed disease. On the other hand, women are especially targeted by Von Willebrand infection due to their menstrual cycle. This extensive pool of patients is being treated with some treatment method; thus, the market for coagulation factor treatment has been growing.
The high expense of treatment is a significant barrier to the market. Daily outpatient appointments, hospitalization, and lab studies entail high costs unaffordable for middle-income nations such as Asia and Africa; thus, the consequence of coagulation factors treatments in those regions is stagnant.
Many replacement drugs have been developed with simpler administration methods, lower immunogenicity, greater potency, and longer half-lives. Bioengineering advances have been helping in treating coagulation disorders for the past five years. These advancements increase the coagulation factor treatment market growth.
Freeze-dried injection dominates the global human coagulation market based on the type segment.
Analyst support
After evaluating your requirements and addressing your technical problems, the expert analyst will resolve your query directly.
Customer satisfaction
According to your needs, our expert team will assist you with the capabilities, services, and proper research needs to be required and customize the report accordingly.
Inimitable expertise
Our expert team will create unrivaled reviews to provide you with a deep understanding of the reports.
Assured quality
We have created a systematic way to determine standards and satisfy your expectations.
Instant delivery
Unlike others, we provide you a great deal of instant delivery in the form of PDF/PPT/Word Doc directly to your email address within 24 hours after receiving full payment.
Privacy policy
We understand the inkling of your privacy, we will never misuse your email address.
Custom research service
We are giving you an opportunity through which you can directly ask our expert analyst to customize an exclusive study of the report to serve your research needs.
Quality & accuracy
We provide you with the accurate quality of the customized study of an exclusive report according to your research need.
Data visualization
As the business world’s growing faster every day, we understand the value of data management. We will create the reports by keeping all the visual data sets and metrics in the charts.
Information security
We truly respect your privacy and promise to keep your personal and confidential information safe and secure.